Raw data of the publication: Does moderate hyperkalemia influence survival in HF? Insights from the MECKI score data (Int J Cardiol . 2023 Jan 15;371:273-277. doi: 10.1016/j.ijcard.2022.09.030. Epub 2022 Sep 15)

<strong>Background: </strong>The prognostic role of moderate hyperkalemia in reduced ejection fraction (HFrEF) patients is still controversial. Despite this, it affects the use of renin-angiotensin-aldosterone system inhibitors (RAASi) with therapy down-titration or discontinuation. <strong>Objectives: </strong>Aim of the study was to assess the prognostic impact of moderate hyperkalemia in chronic HFrEF optimally treated patients. <strong>Methods and results: </strong>We retrospectively analyzed MECKI (Metabolic Exercise test data combined with Cardiac and Kidney Indexes) database, with median follow-up of 4.2 [IQR 1.9-7.5] years. Data on K⁺ levels were available in 7087 cases. Patients with K⁺ plasma level ≥ 5.6 mEq/L and &lt; 4 mEq/L were excluded. Remaining patients were categorized into normal &gt;4 and &lt; 5 mEq/L (n = 4826, 68%) and moderately high ≥5.0 and ≤ 5.5 mEq/L (n = 496, 7%) K⁺. Then patients were matched by propensity score in 484 couplets of patients. MECKI score value was 7% [IQR 3.1-14.1%] and 7.3% [IQR 3.4-15%] (p = 0.678) in patients with normal and moderately high K⁺ values while cardiovascular mortality events at two years follow-up were 41 (4.2%) and 33 (3.4%) (p = 0.333) in each group respectively. <strong>Conclusions: </strong>Moderate hyperkalemia does not influence patients' outcome in a large cohort of ambulatory HFrEF patients.